T. F. Eleveld

Recurrence of a Mediastinal Germ-Cell Tumor as a Somatic-Type Malignancy: A Complex Case Report

L. Looijenga, A. Gillis, M. Kranendonk, 2021, International journal of molecular sciences.

Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors

L. Looijenga, L. Dorssers, A. Gillis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

B. Ylstra, L. Looijenga, J. Molenaar, 2022, Frontiers in Oncology.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

Gudrun Schleiermacher, Jan Koster, Javed Khan, 2015, Nature Genetics.

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

R. Versteeg, H. Caron, J. Koster, 2023, Frontiers in Oncology.

MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma

R. Versteeg, H. Caron, J. Koster, 2020, bioRxiv.

RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.

D. Zwijnenburg, R. Versteeg, J. Koster, 2018, Cancer research.

The Role of TP53 in Cisplatin Resistance in Mediastinal and Testicular Germ Cell Tumors

L. Looijenga, A. Gillis, Sanne Hillenius, 2021, International journal of molecular sciences.

Engineering large-scale chromosomal deletions by CRISPR-Cas9

B. Ylstra, P. Eijk, L. Vriend, 2021, Nucleic acids research.

Engineering large chromosomal deletions by CRISPR-Cas9

B. Ylstra, P. Eijk, P. Poddighe, 2020, bioRxiv.

Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers

David T. W. Jones, S. Pfister, G. Vassal, 2020, European journal of cancer.